In the first clinical trial, the CD22-targeting rIT BL22 achieved a high rate of objective responses in HCL patients but failed to show activity in CLL, follicular lymphoma, MCL [3], and ALL [4]. Here, CD22 is linked to mantle cell lymphoma.